Early Intervention with Drugs Offers Migraine Relief

Sumatriptan/naproxen sodium associated with less pain, nausea, photophobia when taken soon after migraine onset

TUESDAY, July 8 (HealthDay News) -- Taking a single-tablet formulation of sumatriptan and naproxen sodium soon after the onset of migraine was effective and well-tolerated for treating traditional and non-traditional symptoms, according to research published in the July 8 issue of Neurology.

Stephen D. Silberstein, M.D., of Thomas Jefferson University in Philadelphia, and colleagues analyzed data from a pair of identically designed studies in which 576 and 535 migraineurs were randomized to receive sumatriptan/naproxen or placebo, taking it within an hour of migraine head pain.

At two hours, 52 and 51 percent of patients in the treatment groups were pain-free, compared to 17 and 15 percent of patients in the placebo groups, the researchers report. At two and four hours, the treatment led to lower rates of nausea, photophobia, phonophobia, neck discomfort and sinus pressure. The most common adverse events in the treatment groups were nausea and dizziness, the report notes.

"Addressing multiple mechanisms of the migraine process by combining medications that target peripheral, central, and neuronal sites of action with early intervention prior to the establishment of central sensitization is a rational strategy for the acute treatment of migraine. These replicate studies demonstrate that the fixed-dose single-tablet formulation of sumatriptan/naproxen is an effective and well-tolerated therapy when administered during mild migraine pain within one hour of onset. Physicians and patients should consider utilizing both multimechanistic therapy and early intervention as an effective strategy for achieving the best clinical outcomes," the authors conclude.

Silberstein and co-authors disclosed relationships with a variety of pharmaceutical companies; several co-authors work for GlaxoSmithKline. The study was sponsored by Pozen, Inc., and supported by GlaxoSmithKline.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing